<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432020000600005</article-id>
<article-id pub-id-type="doi">10.7399/fh.11525</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain]]></article-title>
<article-title xml:lang="es"><![CDATA[Coste de eltrombopag y rituximab por paciente respondedor al tratamiento de la trombocitopenia inmune primaria en España]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Porras]]></surname>
<given-names><![CDATA[José Ramón]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Parrondo García]]></surname>
<given-names><![CDATA[Francisco Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Anguita]]></surname>
<given-names><![CDATA[Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universitario de Salamanca-IBSA Hematology Department, Hospital ]]></institution>
<addr-line><![CDATA[Salamanca ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,JParrondoHEALTH  ]]></institution>
<addr-line><![CDATA[Coslada Madrid]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Clínico San Carlos Hematology Department, IML, IdISSC Medical School, Department of Medicine, Complutense University (UCM)]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>44</volume>
<numero>6</numero>
<fpage>279</fpage>
<lpage>287</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432020000600005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432020000600005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432020000600005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: Splenectomy, thrombopoietin receptor agonists and rituximab are the second-line treatments for steroid-resistant adult primary immune thrombocytopenia. The last two are becoming the most widely used treatments to avoid splenectomy adverse effects and inconveniences. However, the choice between rituximab and thrombopoietin receptor agonists is unclear. Therefore, the treatment cost may be of particular interest to prioritize the therapy option. Our aim is to determine the cost per responding-patient after 6 months of use of rituximab compared to thrombopoietin receptor agonists eltrombopag in the treatment of chronic primary immune thrombocytopenia in the Spanish National Health Service.  Method: A 26-week decision tree model was developed to assess the cost of treatment response of adult patients with chronic-refractory primary immune thrombocytopenia to eltrombopag and rituximab from the perspective of the Spanish National Health System. Effectiveness was obtained from the literature, and cost was obtained from the official rates. Costs were expressed in &#8364; (2018). Due to the short period of assessment, no discount rate was applied.  Results: The average cost per patient after 6 months of treatment was slightly higher for eltrombopag (&#8364;13,089.40) than for rituximab (&#8364;11,852.60). However, the greater response rate of eltrombopag decreases the bleeding costs, resulting in a 29% higher cost per responding-patient with rituximab (&#8364;18,964.15) than for eltrombopag (&#8364;14,732.65). This result is consistent with the results of the 15 sensitivity analyses carried out where eltrombopag always represents a lower cost per responding patient, except in the sensitivity analysis in which treatment with eltrombopag is performed at its maximum dose (75mg). Only in this case, the cost per responder of eltrombopag is &#8364;48 more expensive than that of rituximab. Likewise, the greatest difference in favor of eltrombopag occurs in the scenario that uses the minimum dose of this drug -25mg- (eltrombopag &#8364;7,622.14 compared to &#8364;18,964.15 for rituximab). Thus, the cost per responding patient is lower in eltrombopag even if a second cycle of retreatment with rituximab is not performed (&#8364;14,732.65 versus &#8364;15,298.61).  Conclusions: The treatment cost of rituximab, including monitoring and bleeding costs, is higher than eltrombopag, favoring the latter over rituximab treatment.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: La esplenectomía, los agonistas del receptor de trombopoyetina y el rituximab son los tratamientos de segunda línea para la trombocitopenia inmune primaria. Los dos últimos se están convirtiendo en los más utilizados para evitar los efectos adversos de la esplenectomía. Sin embargo, la elección entre ambos no está clara. El coste puede ser de interés para priorizar el tratamiento. Nuestro objetivo es determinar el coste por paciente respondedor después de 6 meses de tratamiento de la trombocitopenia inmune primaria crónica con rituximab frente al agonista del receptor de trombopoyetina eltrombopag en el Sistema Nacional de Salud español.  Método: Se desarrolló un modelo de árbol de decisión de 26 semanas para evaluar el coste de la respuesta al tratamiento con eltrombopag y rituximab en pacientes adultos con trombocitopenia inmune primaria crónica refractaria a esteroides. Debido al corto periodo de evaluación, no se aplicó tasa de descuento.  Resultados: El coste medio por paciente tras 6 meses de tratamiento fue ligeramente superior para eltrombopag (13.089,40 &#8364;) que para rituxi mab (11.852,60 &#8364;). Sin embargo, la mayor tasa de respuesta de eltrombopag disminuye los costes de hemorragia, lo que se traduce en un coste por paciente respondedor un 29% mayor con rituximab (18.964,15 &#8364;) que con eltrombopag (14.732,65 &#8364;). Este resultado concuerda con los de los 15 análisis de sensibilidad realizados, donde eltrombopag siempre representa un menor coste por paciente respondedor, excepto cuando el tratamiento con eltrombopag se realiza en su dosis máxima (75 mg). Sólo en este caso, el coste por respondedor a eltrombopag es 48 &#8364; más caro que el del rituximab. En coherencia con lo anterior, la mayor diferencia a favor de eltrombopag se da en el escenario que utiliza la dosis mínima de éste -25 mg- (eltrombopag 7.622,14 &#8364; frente a 18.964,15 &#8364; de rituximab). Así, el coste por paciente respondedor es menor en eltrombopag aunque no se realice un segundo ciclo de retratamiento con rituximab (14.732,65 &#8364; frente a 15.298,61 &#8364;).  Conclusiones: El coste del tratamiento con rituximab, incluidos los costes de monitorización y sangrado, es más alto que el de eltrombopag, lo cual favorece a este último por encima de rituximab.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Pharmacoeconomics]]></kwd>
<kwd lng="en"><![CDATA[Hematologic agents]]></kwd>
<kwd lng="en"><![CDATA[Hematologic diseases]]></kwd>
<kwd lng="en"><![CDATA[Cost analysis]]></kwd>
<kwd lng="en"><![CDATA[Immune thrombocytopenia]]></kwd>
<kwd lng="en"><![CDATA[Thrombopoietin receptor agonists]]></kwd>
<kwd lng="en"><![CDATA[Eltrombopag]]></kwd>
<kwd lng="en"><![CDATA[Rituximab.]]></kwd>
<kwd lng="es"><![CDATA[Farmacoeconomía]]></kwd>
<kwd lng="es"><![CDATA[Fármacos hematológicos]]></kwd>
<kwd lng="es"><![CDATA[Enfermedades hematológicas]]></kwd>
<kwd lng="es"><![CDATA[Análisis de costes]]></kwd>
<kwd lng="es"><![CDATA[Trombocitopenia inmune primaria]]></kwd>
<kwd lng="es"><![CDATA[Agonistas del receptor de trombopoyetina]]></kwd>
<kwd lng="es"><![CDATA[Eltrombopag]]></kwd>
<kwd lng="es"><![CDATA[Rituximab]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodeghiero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Stasi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gernsheimer]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Michel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Provan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2009</year>
<volume>113</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2386-93</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Vicente García]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Grande]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jarque]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[(Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia)]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2012</year>
<volume>138</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>261.e1-261.e17</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schoonen]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
<name>
<surname><![CDATA[Kucera]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Coalson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rutstein]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mowat]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[a]]></surname>
<given-names><![CDATA[et]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2009</year>
<volume>145</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>235-44</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodeghiero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ruggeri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ITP and international guidelines: what do we know, what do we need]]></article-title>
<source><![CDATA[Presse Med]]></source>
<year>2014</year>
<volume>43</volume>
<numero>4 Pt 2</numero>
<issue>4 Pt 2</issue>
<page-range>e61-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kahn]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[McCrae]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Splenectomy in immune thrombocytopenic purpura: recent controversies and long-term outcomes]]></article-title>
<source><![CDATA[Curr Hematol Rep]]></source>
<year>2004</year>
<volume>3</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>317-23</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubin]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Schaffner]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical practice. Care of the asplenic patient]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>371</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>349-56</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neunert]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence-based management of immune thrombocytopenia: ASH guideline update]]></article-title>
<source><![CDATA[Hematology Am Soc Hematol Educ Program]]></source>
<year>2018</year>
<volume>2018</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>568-75</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González-Porras]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Bastida]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety]]></article-title>
<source><![CDATA[Ther Adv Drug Saf]]></source>
<year>2018</year>
<volume>9</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>263-85</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bussel]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Saleh]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Psaila]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kovaleva]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Meddeb]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2007</year>
<volume>357</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2237-47</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grainger]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Locatelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Chotsampancharoen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Donyush]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pongtanakul]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Komvilaisak]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eltrombopag for children with chronic immune thrombocytopenia(PETIT2): a randomised, multicentre, placebo-controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2015</year>
<volume>386</volume>
<numero>10004</numero>
<issue>10004</issue>
<page-range>1649-58</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tarantino]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Bussel]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Blanchette]]></surname>
<given-names><![CDATA[VS]]></given-names>
</name>
<name>
<surname><![CDATA[Despotovic]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Raj]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>388</volume>
<numero>10039</numero>
<issue>10039</issue>
<page-range>45-54</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Saleh]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Marcher]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vasey]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mayer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Aivado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2011</year>
<volume>377</volume>
<numero>9763</numero>
<issue>9763</issue>
<page-range>393-402</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bylsma]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Fryzek]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Cetin]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Callaghan]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bezold]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting]]></article-title>
<source><![CDATA[Am J Hematol]]></source>
<year>2019</year>
<volume>94</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>118-32</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bussel]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Kuter]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[George]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[McMillan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Aledort]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Conklin]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2006</year>
<volume>355</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1672-81</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Summary of Product Characteristics: Revolade (eltrombopag)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Mingot]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Valcárcel]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vicente García]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Perrin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Campos Tapias]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2015</year>
<volume>144</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>389-96</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brah]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chiche]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fanciullino]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bornet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mancini]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schleinitz]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey]]></article-title>
<source><![CDATA[Ann Hematol]]></source>
<year>2012</year>
<volume>91</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>279-85</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Summary of Product Characteristics: Mabthera (rituximab)]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González-López]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pascual]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez-Román]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Fuertes]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-González]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Caparros]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia]]></article-title>
<source><![CDATA[Am J Hematol]]></source>
<year>2015</year>
<volume>90</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>E40-3</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Dentali]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Crowther]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sigouin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2007</year>
<volume>146</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-33</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Du Bois]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Du Bois]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A formula to estimate the approximate surface area if height and weight be known]]></article-title>
<source><![CDATA[Nutrition]]></source>
<year>1989</year>
<volume>5</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>303-11</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="">
<collab>Instituto Nacional de Estadística</collab>
<source><![CDATA[European Survey of Health in Spain 2014]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fogarty]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Tarantino]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Brainsky]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Signorovitch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Grotzinger]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2012</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>79-87</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Djulbegovic]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Shamai-Lubovitz]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Mozes]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2000</year>
<volume>160</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1630-8</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parrondo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Grande]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ibáñez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Palau]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Páramo]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Villa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic evaluation of Thrombopoietin Receptor Agonists in the treatment of chronic primary immune thrombocytopenia]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2013</year>
<volume>37</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>182-91</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kristinsson]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Gridley]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hoover]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[Check]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Landgren]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up]]></article-title>
<source><![CDATA[Haematologica]]></source>
<year>2014</year>
<volume>99</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>392-8</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anguita]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Candel]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[González-Del Castillo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martín-Sánchez]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Splenectomy in ITP: we keep removing a healthy functional organ]]></article-title>
<source><![CDATA[Ann Hematol]]></source>
<year>2016</year>
<volume>95</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1911-2</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arai]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Matsui]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kondo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Takaori-Kondo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of treatments for persistent/chronic immune thrombocytopenia: a systematic review and Network meta-analysis]]></article-title>
<source><![CDATA[Platelets]]></source>
<year>2019</year>
<volume>30</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>946-56</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mazza]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Minoia]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Melpignano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Polimeno]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cascavilla]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Di Renzo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a &#8220;real life&#8221; retrospective multicenter experience of the Rete Ematologica Pugliese (REP)]]></article-title>
<source><![CDATA[Ann Hematol]]></source>
<year>2016</year>
<volume>95</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>239-44</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González-López]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez-Román]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Pascual]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-González]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Fuentes]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Jarque]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice]]></article-title>
<source><![CDATA[Eur J Haematol]]></source>
<year>2016</year>
<volume>97</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>297-302</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
